

**MINUTES OF THE MEETING OF THE CUMBRIA AREA PRESCRIBING COMMITTEE
HELD ON THURSDAY 18th FEBRUARY, 2016 AT 2.00PM
PRUFC, PENRITH**

Present:	Bill Glendinning	Chief Pharmacist, NCUHT (Chair)
	Lesley Angell	Senior Medicines Optimisation Pharmacist, NECS
	Pauline Bourne	Senior Pharmacist, UHMBT
	Andrea Loudon	Clinical Pharmacy Lead, CCG
	Dr Andrea Mulgrew	GP Prescribing Lead, Allerdale Locality
	Dr Amanda Pugh	GP Prescribing Lead, Furness Locality
	Sarah Roberts	Patient Voice representative
	Ben Merriman	LPC Representative
	Dr Nirmalan Arulanantham	Clinical Pharmacologist General Physician, NCUHT
	Rebekah Burton	Education & Training Pharmacist, NCUHT
	Phil Utting	Senior Technician, Medicines Optimisation, NECS
	Helen Huck	Head of Pharmacy CPFT

Agenda items 1 to 4.3 in part: Mr Paul Plant, Consultant Chest Physician, NCUHT

APOLOGIES FOR ABSENCE

Action

Apologies for absence were received from:

Dr Julia Smith GP Prescribing Lead, South Lakes Locality

DECLARATION OF INTERESTS

NONE

MINUTES OF THE PREVIOUS MEETING

The minutes of the previous meeting held on 18th December 2015 were agreed with the following amendments:

145/15 1. New patients should be prescribed first line antidepressants Citalopram and Fluoxetine.

153/15 Antibiotic prescriptions recommended by out patient clinics (secondary care) – Noted that if immediate treatment is needed then the secondary care clinician should prescribe, otherwise the GP can be asked to prescribe.

ACTION LOG FROM PREVIOUS MEETING (30 April 2015)

Updates were given as follows:

140/15 – This action was completed

141/15 – This action was completed

142/15 – This action was completed

143/15 – This action was completed

145/15 – This action was completed

149/15 – This action was completed

134/14 – Draft a statement about the second line use of anti-TNFs for psoriatic arthritis in line with the decision of the IFR panel.

LA

Statement was approved in August meeting – to be added to Blueteq. - ONGOING

LA

26/15 – Lothian Annual Declaration of Interest Form – to be developed and completed annually - ONGOING

72/15 - NG 14-Melanoma – assessment & management – Vitamin D guidelines are under review, working group to be set up including MO team BG (NCUHT) and PB (UHMBT) to review and update all current guidelines, to be brought to June 2016 meeting after approval at the relevant Medicine Management Trust groups – ONGOING

LA

BG

PB

108/15 - Guidelines for the use of Feminising Hormone therapy in gender dysphoria -

LA

Currently being localised by MO Team, will be brought back to April 2016 meeting - ONGOING.

109/15 - Guidelines for the use of Masculinising Hormone therapy in gender dysphoria –

LA

Currently being localised by MO Team, will be brought back to April 2016 meeting - ONGOING.

111/15 – Sulfasalazine SCG – For Gastro indications the SCG will be updated with monitoring requirements and brought back to the April 2016 meeting. - ONGOING

PB

126/15 – Azathioprine & Mercaptopurine SCG – LA to review the SCG taking comments from Mr Dennis Burke and Dr Shadad (both NCUHT) into account. - ONGOING

LA

127/15 – LJF Amendments (Nov 2015) – 4.10 (f) Diazepam Prescribing

Current prescribing figures were noted by the group and it was decided that this information should be taken to the Cumbria LIN meeting on the 24.3.16 for a decision on a course of action. - ONGOING

LA

128/15 - TA358 Tolvaptan – For treating autosomal dominant polycystic kidney disease in adults – RED – LA to check commissioner status - ONGOING

LA

131/15 - ALGORITHM FOR BLOOD GLUCOSE LOWERING THERPAY IN ADULTS WITH TYPE 2 DIABETES

LA

Will be reviewed and adapted with local formulary drug choices for Cumbria. - ONGOING

140/15 - Naloxone Safety Alerts - Noted to be added to Prescription Pad. COMPLETED

141/15 - Water for irrigation for home ventilation patients – Noted, the prescription must state the word “infusion” for the patient to receive the correct product. To be added to Prescription Pad. - COMPLETED

142/15 - Impact Assessment: NG20 Coeliac disease: recognition, assessment and management - Noted, to be added to Prescription Pad - COMPLETED

143/15 - Review of liquid PPI Specials (unlicensed preparations) –Final version ratified. - COMPLETED

143/15b - Prescribing review: LHRH Agonists – No response received from NCUHT consultants. Feedback required from NCUHT Consultants, comments to April APC meeting - ONGOING

BG

144/15 - Prescribing review: Antipsychotic drugs –

Recommendation 2 - Written communication will be sought from CPFT Medical Director to support GPs to implement this recommendation. – ONGOING

LA

145/15 - Prescribing review: Antidepressants – Recommendations to be added to Prescription Pad – COMPLETED

149/15 - Deep Vein Thrombosis Pathway

This pathway has been withdrawn. - COMPLETED

01/16 – APC Terms of Reference

Members reviewed the current APC Terms of Reference, BG was confirmed as the Chair and AL was confirmed as the Vice Chairperson. Updated version to be circulated for ratification at the April meeting.

PU

02/16 - Review of COPD Guidance

Mr Paul Plant, Consultant Chest Physician, NCUHT, presented the work being carried out by the Success Regime on COPD. He asked for comments on an algorithm for management of COPD and management and prevention of exacerbations.

The committee preferred Chronic Disease Management Option 1 with the following amendments:

1. Pneumococcal vaccination (repeat after 5 years) **Review pneumococcal vaccination**
2. Theophylline - Prescribe by brand – **Remove Phyllocontin and Nuelin**
3. End of life – Consider: 1st line MST 10-20mg bd – **Change to Zomorph**

The committee raised concerns about the off-label use of budesonide when licensed products existed. Mr Plant explained that there was strong evidence for its use and would include it in the guidelines. The GPs explained that a lot of effort had gone into switching patients to Fostair and patients reported that they were happy with it.

The committee also raised concerns about the choice of dual LABA/LAMA inhalers and from experience of the clinicians around the table some patients are unable to use the devices. Second choice inhalers would be helpful addition in the guidelines.

Amended documents to be brought to the next meeting.

BG

The committee approved the Management and Prevention of Exacerbations with the following amendment:

1. Sputum still purulent – **Change Cotrimoxazole to Trimethoprim if Microbiologists agree**

03/16 – Lothian Joint Formulary Review

Working group to be set up to discuss the options for formulary in light of discrepancies between Lothian and NICE.

LA

Working group members: PB,LA, AL, HH, Chris Brewer – to meet before the April APC

meeting. - ONGOING

04/16 – PresQIPP Drop List

Accepted to adopt the principles of the PresQIPP Drop List for Cumbria. - COMPLETED

05/16 RECENT LJF NEW DRUG RECOMMENDATIONS

Ciclosporin 0.1% eye drops emulsion Ikervis® Treatment for severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. See 06/16 for NICE TA369 decision.

Calcium & Vitamin D supplement theiCal-D3®- Not included. For prevention and treatment of calcium and vitamin D deficiency. It will be used as an adjunct to specific osteoporosis treatments in patients at risk of calcium and vitamin D deficiency. Noted - BLACK

Atomoxetine Oral solution 4mg/ml Strattera® Treatment of attention-deficit/hyperactivity disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. AMBER

Anakinra (Kineret®)– Not recommended - noted - BLACK

Co-careldopa (Duodopa®) – Not recommended - noted – RED – specialist use only

Denosumab (Xgeva®)- Not recommended - noted – RED – in line with TA265

Edoxaban (Lixiana®) –Not included - noted – GREEN – in line with TA355

06/16 NICE TECHNOLOGY APPRAISALS

TA369 Ciclosporin – Ciclosporin (Ikervis) for treating dry eyes that has not improved despite treatment with artificial tears. - AMBER

TA370 Bortezomib – For previously untreated mantle cell lymphoma. RED

TA371 Trastuzumab emtansine – For treating HER-2 positive , unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane.– Not recommended - BLACK

TA372 Apremilast – Apremilast for treating active psoriatic arthritis. .–Not recommended - BLACK

TA373 Abatacept, adalimumab, etanercept and tocilizumab – For treating juvenile idiopathic arthritis. RED

TA374 Erlotinib and gefitinib - Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy. RED

TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab, and abatacept – For rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.

– RED

TA376 Radium -223 dichloride – For treating hormone relapsed prostate cancer with bone metastases – RED

TA377 Enzalutamide - For treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. RED

TA378 Ramcicirumab - For treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy. Not recommended - BLACK

TA379 Nintedanib – For treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.– RED (specialist centres only)

TA380 Panobinostat – For treating multiple myeloma after at least 2 previous treatments. – RED

TA381 Olaparib – For the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy. – RED

TA382 Eltrombopag - For severe aplastic anaemia refractory to immunosuppressive therapy - Unable for recommendation - GREY (pending)

TA383 TNF – Alpha inhibitors Adalimumab Certolizumab pegol Etanercept Golimumab Infliximab - For people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked. RED

07/16 **NICE CLINICAL GUIDELINES**

NG30 Oral Health Promotion: General Dental Practice - Noted

NG31 Care of dying adults in the last days of life - Noted – The APC will be guided by Palliative Medicine Management Group.

NG32 Older people: Independence and mental wellbeing – Noted

NG33 Tuberculosis - Noted (secondary care only)

08/16 **NICE MO BASELINE ASSESSMENT**

AL to share transfer of care audit at the next meeting of the LPN.

AL

Patient safety will be discussed at the next MSO meeting in 2016.

09/16 **CONTRACT MONITORING**

Nothing to discuss

10/16 **MEDICINES SAFETY**

Next meeting March 2016.

CLINICAL MATTERS

- 11/16 **NOAC Guidance** - All guidance provided was reviewed by the committee. The Lancashire Medicine Management Group document "Consensus statement for Oral Anticoagulant Drugs for the prevention of stroke and systemic embolism in adults with Non-Valvular Atrial Fibrillation" was endorsed.
Comment was also made on the 1st Care Cumbria "AF – which NOAC to use" document around its convenience however evidence and references to be provided and drug choices should be in line with NICE guidance. AM to ask the author to provide this for April meeting.- ONGOING AM
- 12/16 **GP concerns over new SCG format** – It was noted that GP practices in the South of Cumbria are just receiving prescription requests from secondary care for amber drugs with no information to reassure that secondary care responsibilities outlined in the SCP have been completed. AP and PB to follow up with UHMBT. - COMPLETED AP
PB
- 13/16 **MAS Formulary** - New formulary approved with additional removal of Ketoconazole shampoo 120ml (POM) and antacid tablets – not recommended by GP's. COMPLETED
- 14/16 **STOPP START Toolkit** –Updated document circulated for comments. Comments back to PU. To be brought to April meeting - ONGOING ALL
- 15/16 **Dapsone SCG** - To be brought back to the next meeting with clarification of " Significant deterioration in renal function" and Immunisation required?
This will also be included in the LES for High Risk Drugs.
Any other comments to PB - ONGOING PB
- 16/16 **Dosulepin Prescribing Guidance Update** – APPROVED - COMPLETED
- 17/16 **North East & Cumbria Horizon Scanning 2016/17** – Noted for information. COMPLETED
- 18/16 **Memantine in combination with AChE RAG Status review** – Dr Darren Reynolds to be asked to attend the April meeting to appeal the current RED status. - ONGOING HH
- 19/16 **Insulin Passport** HH
NCUHT are looking to implement the Insulin passport scheme, UHMBT currently use the plastic cards supplied by the manufacturer. HH to ask Cumbria Diabetes what they recommend. - ONGOING
- 20/16 **Mycophenolate SCG – "Off licence use"** PB
No objections adopting the SCG. Final version to be brought to next meeting.- ONGOING
-

25/16 **E Cigarettes**
RAG rating to be BLACK.

OPERATIONAL
Nothing to report

DRUG SAFETY UPDATE

21/16 Drug Safety Update (December 2015) – Noted, points 2 & 3 add to Prescription Pad LA

22/16 Drug Safety Update (January 2016) – Noted, points 1 & 2 add to Prescription Pad LA

23/16 **FOR INFORMATION**

Minutes received:

Lothian Formulary Committee (16th December, 2015)

ANY OTHER BUSINESS

24/16 **Nalmefene RAG status** – PB sought clarification of RAG status of nalmefene in response to a consultant query – this was confirmed RED

DATE and TIME of next meeting

Thursday, 14th April 2016, 2pm at ENTERPRISE HOUSE, KENDAL
